Document Detail


Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
MedLine Citation:
PMID:  17485026     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A review of six clinical trials of aliskiren involving >5,000 patients with mild to moderate hypertension indicated that this first of a new class of orally active antihypertensive drugs is no more effective than angiotensin-converting enzyme inhibitors (CEIs), angiotensin receptor blockers (ARBs), or diuretics for lowering blood pressure. The starting dose is 150 mg; 300 mg is usually more effective, but 600 mg is no better than 300 mg. Aliskiren in combination with a diuretic appeared to lower blood pressure more than an aliskiren-ARB combination, but still failed to control blood pressure (<140/90) in 50% of the patients. Although aliskiren suppresses plasma renin activity, it causes much greater reactive rises in plasma renin concentration than does any other antihypertensive class tested. Because aliskiren, like CEIs and ARBs, only blocks 90% to 95% of plasma renin, the pressor consequences of its greater reactive increases in plasma renin concentration appear to offset its net ability to lower blood pressure, especially with higher doses. Patients with hyperreactive renin systems (renovascular, advanced, and malignant hypertension) were excluded from all of the trials. Until the possibility is eliminated of inducing increases in blood pressure with aliskiren in patients with highly reactive renin levels, it seems safe and simple to stick to the less expensive, equally effective and widely available generic CEI drugs for treating the renin factor in hypertension.
Authors:
Jean E Sealey; John H Laragh
Related Documents :
3895536 - Control of gastric vascular resistance in cardiogenic shock.
699246 - Angiotensin converting enzyme inhibition in patients with congestive heart failure.
798576 - Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in ...
2852076 - Cellular mechanisms of renin release.
20562696 - Frequent subclinical high-altitude pulmonary edema detected by chest sonography as ultr...
6204146 - Effects of potassium on blood pressure regulation.
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  American journal of hypertension     Volume:  20     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-05-08     Completed Date:  2007-07-24     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  587-97     Citation Subset:  IM    
Affiliation:
Department of Cardiothoracic Surgery, New York Presbyterian Hospital and Weill Medical College of Cornell University, New York, New York., USA. jsealey@med.cornell.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amides / adverse effects,  pharmacology*,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / adverse effects,  pharmacology*,  therapeutic use
Blood Pressure / drug effects
Clinical Trials as Topic
Drug Therapy, Combination
Female
Fumarates / adverse effects,  pharmacology*,  therapeutic use
Humans
Hypertension / drug therapy*
Male
Renin / antagonists & inhibitors*,  blood,  secretion*
Chemical
Reg. No./Substance:
0/Amides; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; EC 3.4.23.15/Renin
Comments/Corrections
Comment In:
Curr Hypertens Rep. 2007 Nov;9(5):389-91   [PMID:  18177585 ]
J Hypertens. 2007 Sep;25(9):1775-82   [PMID:  17762637 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
Next Document:  A review of strontium ranelate and its effect on DXA scans.